<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="direct-acting antivirals (DAAs). The first DAAs, the protease inhibitors (PIs)" exact="boceprevir" post="(BOC) and telaprevir (TVR), were approved in 2011 but"/>
 <result pre="The first DAAs, the protease inhibitors (PIs) boceprevir (BOC) and" exact="telaprevir" post="(TVR), were approved in 2011 but had several limitations."/>
 <result pre="new DAAs have been developed. Approval of the polymerase inhibitor" exact="sofosbuvir" post="(SOF) in January 2014 allowed for IFN-free therapy, which"/>
 <result pre="the first fixed-dose combination of SOF and the NS5A inhibitor" exact="ledipasvir" post="(LDV) was approved, as well as the combination of"/>
 <result pre="considered, especially in the ritonavir-based regimen [20–23]. When looking at" exact="ritonavir" post="in particular, a strong inhibition of CYP 3A4 affects"/>
 <result pre="2016; and (C) August 15, 2016 (first patient treated with" exact="velpatasvir" post="[VEL], elbasvir/grazoprevir [ELB/GRZ], or glecaprevir/pibrentasvir [GLE/PIB], and therefore pangenotypic"/>
 <result pre="analyzed as a single medication. The following DAAs were assessed:" exact="boceprevir" post="(BOC), telaprevir (TVR), daclatasvir (DAC), simeprevir (SIM), sofosbuvir (SOF),"/>
 <result pre="a single medication. The following DAAs were assessed: boceprevir (BOC)," exact="telaprevir" post="(TVR), daclatasvir (DAC), simeprevir (SIM), sofosbuvir (SOF), ombitasvir + paritaprevir + ritonavir ± dasabuvir (OBV/PTV/r ± DSV),"/>
 <result pre="medication. The following DAAs were assessed: boceprevir (BOC), telaprevir (TVR)," exact="daclatasvir" post="(DAC), simeprevir (SIM), sofosbuvir (SOF), ombitasvir + paritaprevir + ritonavir ± dasabuvir (OBV/PTV/r ± DSV), ledipasvir (LDV) + sofosbuvir"/>
 <result pre="following DAAs were assessed: boceprevir (BOC), telaprevir (TVR), daclatasvir (DAC)," exact="simeprevir" post="(SIM), sofosbuvir (SOF), ombitasvir + paritaprevir + ritonavir ± dasabuvir (OBV/PTV/r ± DSV), ledipasvir (LDV) + sofosbuvir (SOF), glecaprevir"/>
 <result pre="were assessed: boceprevir (BOC), telaprevir (TVR), daclatasvir (DAC), simeprevir (SIM)," exact="sofosbuvir" post="(SOF), ombitasvir + paritaprevir + ritonavir ± dasabuvir (OBV/PTV/r ± DSV), ledipasvir (LDV) + sofosbuvir (SOF), glecaprevir (GLE) + pibrentasvir (PIB),"/>
 <result pre="telaprevir (TVR), daclatasvir (DAC), simeprevir (SIM), sofosbuvir (SOF), ombitasvir + paritaprevir + ritonavir ± dasabuvir (OBV/PTV/r ± DSV)," exact="ledipasvir" post="(LDV) + sofosbuvir (SOF), glecaprevir (GLE) + pibrentasvir (PIB), elbasvir (ELB) + grazoprevir (GRZ), velpatasvir"/>
 <result pre="(OBV/PTV/r ± DSV), ledipasvir (LDV) + sofosbuvir (SOF), glecaprevir (GLE) + pibrentasvir (PIB), elbasvir (ELB) + grazoprevir (GRZ)," exact="velpatasvir" post="(VEL) + sofosbuvir (SOF) ± voxilaprevir (VOX). DAAs already withdrawn from the market"/>
 <result pre="DDIs were analyzed for pegylated interferon α (PEG-IFN α) and" exact="ribavirin" post="(RBV). 2. Real-world incidence of DDIs due to antiviral"/>
 <result pre="contrast, patients with kidney transplantation receiving sirolimus, everolimus, cyclosporine, or" exact="tacrolimus" post="increased over time (A: 0.0%, B: 2.3%, C: 4.0%;"/>
 <result pre="2 (0–19) Kidney transplant patients receiving sirolimus, everolimus, cyclosporine, or" exact="tacrolimus" post="16 (2.4) 0 (0) 6 (2.3) 10 (4.0) Abbreviations:"/>
 <result pre="clearly identified based on the description provided by the patient." exact="Pantoprazole" post="(22.0%), levothyroxine (14.4%), and spironolactone (12.3%) were used most"/>
 <result pre="based on the description provided by the patient. Pantoprazole (22.0%)," exact="levothyroxine" post="(14.4%), and spironolactone (12.3%) were used most frequently. Overall,"/>
 <result pre="description provided by the patient. Pantoprazole (22.0%), levothyroxine (14.4%), and" exact="spironolactone" post="(12.3%) were used most frequently. Overall, the top most"/>
 <result pre="medications, antiepileptic drugs (carbamazepine [5 patients], eslicarbazepine [1 patient], and" exact="oxcarbazepine" post="[1 patient]), St. John’s wort (1 patient), and rifampicin"/>
 <result pre="and oxcarbazepine [1 patient]), St. John’s wort (1 patient), and" exact="rifampicin" post="(1 patient) were identified as the medications with the"/>
 <result pre="ELB/GRZ (n = 73), were proton pump inhibitors (PPIs), metamizole, statins, and" exact="carvedilol" post="(Supplementary Table 6). More precise information on relevant DDIs"/>
 <result pre="with first-generation PIs used from 2011 or the combinations with" exact="ritonavir" post="booster used from 2014 [10, 20]. However, our work"/>
 <result pre="EversonGT, GordonSC, et al.collab: PROVE1 Study TeamTelaprevir with peginterferon and" exact="ribavirin" post="for chronic HCV genotype 1 infection. N Engl J"/>
 <result pre="3.FosterGR, HézodeC, BronowickiJP, et al.Telaprevir alone or with peginterferon and" exact="ribavirin" post="reduces HCV RNA in patients with chronic genotype 2"/>
 <result pre="et al.collab: PROVE2 Study TeamTelaprevir and peginterferon with or without" exact="ribavirin" post="for chronic HCV infection. N Engl J Med2009; 360:1839–50.19403903"/>
 <result pre="Int2015; 35:1845–1852.25556625 15.AfdhalN, ZeuzemS, KwoP, et al.collab: ION-1 InvestigatorsLedipasvir and" exact="sofosbuvir" post="for untreated HCV genotype 1 infection. N Engl J"/>
 <result pre="Med2014; 370:1889–98.24725239 16.AfdhalN, ReddyKR, NelsonDR, et al.collab: ION-2 InvestigatorsLedipasvir and" exact="sofosbuvir" post="for previously treated HCV genotype 1 infection. N Engl"/>
 <result pre="Med2014; 370:1483–93.24725238 17.KowdleyKV, GordonSC, ReddyKR, et al.collab: ION-3 InvestigatorsLedipasvir and" exact="sofosbuvir" post="for 8 or 12 weeks for chronic HCV without"/>
 <result pre="18.FeldJJ, KowdleyKV, CoakleyE, et al.Treatment of HCV with ABT-450/r-ombitasvir and" exact="dasabuvir" post="with ribavirin. N Engl J Med2014; 370:1594–603.24720703 19.PoordadF, HezodeC,"/>
 <result pre="Engl J Med2014; 370:1594–603.24720703 19.PoordadF, HezodeC, TrinhR, et al.ABT-450/r-ombitasvir and" exact="dasabuvir" post="with ribavirin for hepatitis C with cirrhosis. N Engl"/>
 <result pre="Med2014; 370:1594–603.24720703 19.PoordadF, HezodeC, TrinhR, et al.ABT-450/r-ombitasvir and dasabuvir with" exact="ribavirin" post="for hepatitis C with cirrhosis. N Engl J Med2014;"/>
 <result pre="al.Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor" exact="simeprevir" post="and frequently used concomitant medications. Br J Clin Pharmacol2018;"/>
 <result pre="28.FosterGR, AfdhalN, RobertsSK, et al.collab: ASTRAL-2 Investigators; ASTRAL-3 InvestigatorsSofosbuvir and" exact="velpatasvir" post="for HCV genotype 2 and 3 infection. N Engl"/>
 <result pre="Med2015; 373:2608–17.26575258 29.FeldJJ, JacobsonIM, HézodeC, et al.collab: ASTRAL-1 InvestigatorsSofosbuvir and" exact="velpatasvir" post="for HCV genotype 1, 2, 4, 5, and 6"/>
 <result pre="Dis2014; 46:67–71.24125691 35.CharltonM, EversonGT, FlammSL, et al.collab: SOLAR-1 InvestigatorsLedipasvir and" exact="sofosbuvir" post="plus ribavirin for treatment of HCV infection in patients"/>
 <result pre="35.CharltonM, EversonGT, FlammSL, et al.collab: SOLAR-1 InvestigatorsLedipasvir and sofosbuvir plus" exact="ribavirin" post="for treatment of HCV infection in patients with advanced"/>
 <result pre="Gastroenterology2015; 149:649–59.25985734 36.MannsM, SamuelD, GaneEJ, et al.collab: SOLAR-2 InvestigatorsLedipasvir and" exact="sofosbuvir" post="plus ribavirin in patients with genotype 1 or 4"/>
 <result pre="36.MannsM, SamuelD, GaneEJ, et al.collab: SOLAR-2 InvestigatorsLedipasvir and sofosbuvir plus" exact="ribavirin" post="in patients with genotype 1 or 4 hepatitis C"/>
</results>
